Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.
Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one
immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have
evidence of disease progression after last therapy. Must have exhausted all available
treatment options accessible as local standard of care and not be eligible for
participation in any ongoing clinical trial. Additional eligibility criteria may be